Literature DB >> 28017442

Prioritizing vaccines for developing world diseases.

Allan Saul1, Katherine L O'Brien2.   

Abstract

A major disparity in the burden of health will need to be addressed to achieve the "Grand Convergence" by 2035. In particular people living in low and middle income countries have a much higher burden of infectious diseases. Although vaccines have been very effective in reducing the global burden of infectious disease, there are no registered vaccines to address 60% of the current burden of infectious disease, especially in developing countries. Thus there is a pressing need for new vaccines and for prioritizing vaccine development given that resources for developing new vaccines are strictly limited. As part of the GLOBAL HEALTH 2035: Mission Grand Convergence meeting one working group assessed the SMART vaccine algorithm as a mechanism for prioritizing vaccine development for diseases of priority in the developing world. In particular, the working group considered which criteria in the standard SMART set were considered "key" criteria and whether other criteria should be considered, when prioritizing vaccines for this important set of countries.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Developing world; Neglected diseases; Prioritization; Strategic Multi-Attribute Ranking Tool; Vaccines

Mesh:

Substances:

Year:  2016        PMID: 28017442     DOI: 10.1016/j.vaccine.2016.10.087

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Fresh approaches to vaccine development: New financial and economic models are required to bring more vaccines against a wider range of diseases to the market.

Authors:  Adam Gristwood
Journal:  EMBO Rep       Date:  2018-07-12       Impact factor: 8.807

2.  Pathway towards an ideal and sustainable framework agreement for the public procurement of vaccines in Spain: a multi-criteria decision analysis.

Authors:  N Zozaya González; B Alcalá Revilla; P Arrazola Martínez; J R Chávarri Bravo; I Cuesta Esteve; A J García Rojas; F Martinón-Torres; E Redondo Margüello; A Rivero Cuadrado; S Tamames Gómez; J Villaseca Carmena; A Hidalgo-Vega
Journal:  Hum Vaccin Immunother       Date:  2020-04-03       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.